Follistatin-344 vs Sermorelin.

Follistatin-344 (FS-344) is an alternatively spliced isoform of human follistatin, a naturally occurring secreted glycoprotein that acts as a high-affinity antagonist of several TGF-beta superfamily ligands. The "344" refers to a 344-amino-acid precursor variant; relative to the longer FS-315 serum isoform, it lacks the C-terminal acidic tail and was selected for therapeutic use partly to reduce off-target heparin/cell-surface binding. In gene-therapy programs it is the FS344 transgene that is delivered, not an injected peptide product, although it is now marketed in gray-market channels as a "research peptide."

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release growth hormone (GH). This 1-29 fragment is the shortest portion of GHRH that retains full biological activity, so sermorelin behaves as a functional GHRH analog (a "secretagogue") rather than as growth hormone itself. It was marketed under the brand names Geref and Geref Diagnostic.

Follistatin works by binding and neutralizing myostatin (GDF-8) and related ligands such as activin A, GDF-11, and several BMPs, preventing them from engaging activin type II receptors. Because myostatin is a dominant negative regulator of skeletal muscle mass, removing this brake promotes satellite-cell activation, myofiber hypertrophy, and reduced fibrosis. Critically, follistatin neutralizes a broader set of ligands than myostatin-only blockade, which is why follistatin overexpression produces larger muscle gains in animals than myostatin knockout alone. The foundational biology traces to McPherron, Lawler and Lee (Nature, 1997), who showed myostatin loss roughly doubles muscle mass in mice.

Sermorelin binds the GHRH receptor on pituitary somatotroph cells, a Gs-protein-coupled receptor, raising intracellular cAMP and stimulating synthesis and pulsatile secretion of endogenous growth hormone. Because it acts upstream on the pituitary rather than supplying exogenous GH, its effect is gated by an intact pituitary and remains subject to normal physiological brakes, most importantly negative feedback from somatostatin and from GH/IGF-1. Downstream, any GH released drives hepatic production of insulin-like growth factor 1 (IGF-1). This "releaser" mechanism is the basis for the long-standing claim that sermorelin produces a more physiologic, pulsatile GH profile than direct recombinant GH injection, though that pharmacodynamic difference has not been shown to translate into superior clinical outcomes.

Human evidence is limited to two small, open-label AAV1-delivered FS344 gene-therapy trials from Nationwide Children's Hospital (Mendell and colleagues), not to any injected-peptide product. A Phase 1/2a trial in Becker muscular dystrophy (6 subjects; Mol Ther 2015, PMID 25322757) reported six-minute-walk gains in some treated patients (e.g., +58 m and +125 m in two subjects) with histological evidence of reduced fibrosis and fiber hypertrophy. A companion sporadic inclusion body myositis trial (6 subjects; Mol Ther 2017, PMID 28279643) reported improved annualized six-minute-walk distance versus untreated controls, though responses were heterogeneous and the comparison used a non-randomized matched control group. These are early-phase, unblinded, very small studies; large-animal support comes from a nonhuman-primate follistatin gene-delivery study (Kota et al., Sci Transl Med 2009, PMID 20368179). No randomized controlled trial, and no trial of FS-344 as a standalone injectable peptide, has demonstrated efficacy. The sIBM functional claims also drew a published methodological critique in Molecular Therapy.

The strongest human evidence is in pediatric diagnostics and idiopathic GH deficiency: sermorelin was studied and FDA-approved both as a provocative test of pituitary GH reserve and for treating growth failure in children with GHRH-responsive (hypothalamic) GH deficiency, where it can increase growth velocity (reviewed in BioDrugs 1999, PMID 18031173). Evidence for the popular adult "anti-aging," body-composition, sleep, and recovery claims is largely mechanistic or extrapolated rather than demonstrated; a frequently cited Clinical Interventions in Aging review (PMID 18046908) frames sermorelin in adult GH insufficiency as a rational but largely hypothetical approach, not an outcome-proven therapy. Notably, the well-known randomized controlled trial showing cognitive benefit from a GHRH analog in older adults and mild cognitive impairment (Baker et al., Archives of Neurology 2012, PMID 22869065) used tesamorelin, a different stabilized GHRH(1-44) analog, not sermorelin, so it should not be cited as direct sermorelin evidence. Overall, robust randomized trials of sermorelin for adult quality-of-life, longevity, or athletic outcomes are essentially absent.

In the two small gene-therapy trials, intramuscular AAV1.FS344 was reported as generally well tolerated over follow-up exceeding two years, but these cohorts are far too small to characterize real risk. Because follistatin broadly inhibits TGF-beta/activin signaling, theoretical and preclinical concerns include effects on reproductive tissues (follistatin was first identified as an inhibitor of FSH secretion), the pituitary-gonadal axis, vascular and cardiac remodeling, and possible influence on tumor biology, none of which are adequately resolved in humans. Gray-market "follistatin-344 peptide" products carry the additional, unquantified hazards of unverified identity, purity, sterility, and the fundamental mismatch that human data come from a delivered gene, not an injected protein. There is no established human safety profile for self-administered FS-344.

In its approved pediatric and diagnostic use, sermorelin was generally well tolerated, with the most common reactions being transient injection-site reactions (redness, swelling, pain) and, less often, flushing, headache, dizziness, or transient warmth; uncommon hypersensitivity reactions were reported. Because it raises GH and IGF-1, the theoretical class concerns that apply to GH-axis stimulation are relevant, including fluid retention, joint or muscle discomfort, insulin resistance/glucose changes, and the general caution around GH-axis stimulation in people with active malignancy. Most safety data come from short-term, monitored, mostly pediatric settings; long-term safety of chronic adult use, especially via compounded products sold for off-label "wellness" purposes, has not been established, and compounded preparations carry additional uncertainty around purity, sterility, and dose accuracy. No doses or regimens are provided here.

Follistatin-344 is not approved by the FDA (or any major regulator) for any indication; it has only been studied investigationally as an AAV-delivered gene therapy and is sold elsewhere strictly as a research-use-only chemical, not a medicine. Myostatin-pathway inhibition is also of interest to anti-doping bodies, and follistatin/myostatin inhibitors fall under WADA's prohibited categories.

Sermorelin acetate was FDA-approved (brand Geref / Geref Diagnostic) for diagnostic testing of pituitary GH reserve and for idiopathic GH deficiency in children, but the branded products were voluntarily withdrawn from the US market in 2008 for commercial reasons (not for safety or efficacy failures); it is currently available in the US only as a compounded preparation, with no FDA-approved finished-drug product on the market.